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a b s t r a c t
HIV patients with severe periodontitis have high levels of residual virus in their saliva and plasma
despite effective therapy (HAART). Multiple short chain fatty acids (SCFAs) from periodontal pathogens
reactivate HIV-1 in both Jurkat and primary T-cell models of latency. SCFAs not only activate positive
transcription elongation factor b (P-TEFb), which is an essential cellular cofactor for Tat, but can also
reverse chromatin blocks by inducing histone modiﬁcations. SCFAs simultaneously increase histone
acetylation by inhibiting class-1/2 histone deacetylases (HDACs) and decrease repressive histone tri-
methylation at the proviral LTR by downregulating expression of the class-3 HDAC sirtuin-1 (SIRT1), and
the histone methyltransferases enhancer of Zeste homolog 2 (EZH2) and suppressor of variegation 3–9
homolog 1 (SUV39H1). Our ﬁndings provide a mechanistic link between periodontal disease and
enhanced HIV-1 replication, and suggest that treatment of periodontal disease, or blocking the activities
of SCFAs, will have a therapeutic beneﬁt for HIV patients.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Periodontal pathogens and viruses, such as HIV, interact with each
other in the oral arena to exacerbate disease progression (Mataftsi
et al., 2011). Periodontal disease is initiated by infections with period-
ontal pathogens such as Porphyromonas gingivalis (Pg) and is associated
with chronic inﬂammation (Holt et al., 1988; Pihlstrom et al., 2005).
Larger numbers of bacteria responsible for periodontal disease have
been found in the plaques of HIV-positive individuals than that of HIV-
negative people (Chattin et al., 1999; Ramos et al., 2012; Zambon et al.,
1990) and there is an increased prevalence and severity of chronic
periodontitis in HIV-positive subjects (Mataftsi et al., 2011; Phiri et al.,
2010; Tukutuku et al., 1990). Thus, HIV infection may predispose the
patients to chronic periodontitis as a result of immune deﬁciency,
while periodontal pathogens may enhance HIV infection and replica-
tion in the oral cavity, creating a vicious cycle of co-infections.
Anaerobic gram-negative bacteria such as Pg and Fusobacterium
nucleatum (Fn) produce at least ﬁve different short chain fatty acids
(SCFAs) as metabolic by-products (Niederman et al., 1996, 1997).
Millimolar levels of the different SCFAs are found in the gingival
crevicular ﬂuid of patients with severe periodontal disease while
they are undetectable in the gingival crevicular ﬂuid of healthy
individuals (Niederman et al., 1996, 1997). One of the SCFAs, butyric
acid, was previously identiﬁed from the culture supernatants of Pg
and Fn as the molecule responsible for stimulating HIV-1 transactiva-
tion (Imai and Ochiai, 2011; Imai et al., 2009, 2012a, 2012b, 2012c;
Kantor et al., 2009). Butyric acid inhibits class-1/2 histone deacety-
lases (HDACs), leading to histone hyperacetylation and induction of
viral gene expression and replication. Different than the previous
reports, we recently demonstrated that the different SCFAs from
periodontal pathogens dose-dependently and additively promote
lytic replication of Kaposi’s sarcoma-associated herpesvirus (KSHV)
in acutely infected oral epithelial cells and latently infected B
lymphocytes (Yu et al., 2014). Therefore, it would be interesting to
test if the different SCFAs have similar effects on HIV, which is a very
different virus.
Since cytokines and bacterial metabolic products released
during inﬂammation are known to stimulate HIV transcription
and productive replication, the infected oral cavity can become a
site of enhanced viral replication (Baﬁca et al., 2004; Mbopi-Keou
et al., 2002). In a chronic inﬂammation milieu such as gingivitis,
CD4þ T-cells that are latently infected by HIV are likely present along
with uninfected T-cells and macrophages (Fenouillet et al., 1989;
Le Naour et al., 1992; Mabondzo et al., 1991; Neuveut et al., 1991;
von Briesen et al., 1990). We therefore postulated that when latently
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Fig. 1. Culture supernatants of periodontal pathogens Pg and Fn induce HIV-1 transactivation in HIV-1 latently infected Jurkat T-cells. (A) Diagram of the HIV-1 provirus,
which is integrated in chromosome 16 at the methionine sulfoxide reductase B1 (MSRB1) locus in Jurkat T-cells, clone 2D10 (Jadlowsky et al., 2014). The provirus carries the
ﬂuorescent d2EGFP protein in place of the Nef gene as a marker for transcriptional activation. (B) Flow cytometry histograms showing differences in GFP expression in 2D10
cells treated with fresh medium (bacteria negative control), culture supernatant of Ec (non-oral bacteria and SCFAs-negative control), and culture supernatants of periodontal
pathogens Pg and Fn at 1 (bacterial supernatant volume) to 25 (total cell culture medium volume) dilution for 24 h, respectively. (C) Dose-dependent induction of GFP-
expression in 2D10 cells by supernatants of Pg and Fn. Identical amounts of 2D10 cells were treated with different concentrations (2%, 4%, 6%, 8%, and 10% bacterial
supernatant volume vs. total culture medium volume) of Pg and Fn supernatants for 24 h. (D) Fraction of GFP-positive cells in 2D10 cells treated with fresh medium,
supernatants of Pg and Fn, ﬁltered Fn supernatant with other bacterial by-products removed while retaining SCFAs, and ﬁltered and heated Fn supernatant with all bacterial
by-products including SCFAs removed, respectively.
B. Das et al. / Virology 474 (2015) 65–8166
infected CD4þ T-cells are exposed to this environment of bacterial
infection and chronic inﬂammation, the proviruses will become
reactivated and this will lead to the release of infectious virus.
In the present study, we investigated whether the different SCFAs
can induce latent HIV-1 proviral transcription in T-cells. Several
features of the metabolism of resting CD4þ T-cells work in an
interdependent manner to ensure that latent proviruses remain
transcriptionally inactive. First, quiescent T-cells contain minimal levels
of P-TEFb, a cellular elongation factor that is an essential cofactor for
the HIV transactivator protein Tat and strictly required for efﬁcient HIV
transcription (Wei et al., 1998). In resting T-cells, CycT1 is expressed at
minimal levels preventing P-TEFb assembly (Ghose et al., 2001).
Second, epigenetic silencing due to recruitment of histone deacetylases
(HDACs), histone methyltransferases (du Chene et al., 2007; Friedman
et al., 2011; Keedy et al., 2009; Pearson et al., 2008) and DNA
methylation (Blazkova et al., 2009; Kauder et al., 2009) greatly restrict
transcription initiation during latency. Finally, the transcription initia-
tion factors NF-κB and NFAT, which are used to reverse chromatin
blocks on latent proviruses, are sequestered in the cytoplasm (Bosque
and Planelles, 2008; Kinoshita et al., 1997; Nabel and Baltimore, 1987).
Despite these multiple restrictions, stimulation of memory T-cells by
cytokines or by T-cell receptor activation provides a powerful signal
leading to the resumption of HIV transcription, replication and spread.
We found that all SCFAs, except for acetic acid, are able to potently
stimulate latent HIV-1 transcription in both Jurkat-T cells and primary
CD4þ T-cells in a dose-dependent and additive manner. Similar to our
observations on the activation of KSHV in acutely infected oral
epithelial cells and latently infected B lymphocytes (Yu et al., 2014),
we found that SCFAs potently inhibit the activity of class-1/2 HDACs in
T-cells. In addition, SCFAs downregulate expression of the class-3
HDAC SIRT1 (sirtuin-1, silent information regulator-1), which is a
NADþ-dependent HDAC (Guarente, 2000). SCFAs also downregulate
expression of EZH2 (enhancer of Zeste homolog2) and SUV39H1
(suppressor of variegation 3–9 homolog1), two histone lysine methyl-
transferases (HLMTs) that suppresses gene expression through
histone-3 (H3) di- and tri-methylation at Lys27 and Lys9, respectively
(Cao et al., 2002; Schotta et al., 2003; Sewalt et al., 2002; Shinkai and
Tachibana, 2011). Thus, SCFAs simultaneously increase histone acetyla-
tion and decrease repressive histone methylation at the proviral
promoter. These histone modiﬁcations in the promoter region have
been previously associated with transactivation of the HIV provirus
(Bernhard et al., 2011; Bouchat et al., 2012; du Chene et al., 2007;
Friedman et al., 2011; Marban et al., 2007; Pearson et al., 2008; Tyagi
et al., 2010; Van Lint et al., 1996; Verdin et al., 1993). Unexpectedly, we
also found that SCFAs induce phosphorylation of CDK9 and upregulate
expression of CyclinT1 to activate the positive transcription elongation
factor b (P-TEFb), which is essential for active transcription elongation
of the HIV-1 provirus (Karn, 2013; Massari et al., 2013; Mbonye et al.,
2013; Novis et al., 2013). Because of their ability to upregulate P-TEFb,
SCFAs are able to stimulate HIV production in primary resting memory
T-cells. The novel mechanisms by which SCFAs transactivate latent
HIV-1 proviruses provide new insights into how periodontal patho-
gens contribute to HIV-1 replication and suggest that treatment of
periodontal disease, and/or blocking the activities of SCFAs, will have a
therapeutic beneﬁt for HIV patients.
Results
Culture supernatants of periodontal pathogens strongly induce HIV-1
transactivation
The culture supernatants of the periodontal pathogens Pg and
Fn have been shown previously to induce HIV-1 transactivation
(Imai et al., 2009, 2012c). Using a latently infected Jurkat T-cell line
(2D10) carrying a ﬂuorescent reporter in the provirus (Fig. 1A)
(Friedman et al., 2011; Jadlowsky et al., 2014; Pearson et al., 2008),
we observed similar effects of the bacterial supernatants on
induction of latent HIV-1 proviruses. As shown in Fig. 1B, treat-
ment with fresh medium (control) and supernatant of the non-
oral bacteria Ec resulted in 3.46% and 3.65% of cells expressing the
GFP marker respectively. In contrast, when the cells were stimu-
lated with culture supernatants of Pg and Fn at a 1 to 25-fold
dilution, 90.87% and 91.69% of the cells became GFP-positive,
respectively. In addition, the amounts of GFP-positive cells
increased in a dose-dependent manner (Fig. 1C) when 2D10 cells
were treated with different dilutions of Pg and Fn supernatants.
Since bacteria in the culture supernatants of Pg and Fn had
been eliminated by passing through a 0.22 μM ﬁlter, the bacterial
metabolic by-products in the supernatants were likely responsible
for the potent induction of HIV-1 transactivation. Pg and Fn
produce multiple metabolic by-products including high molecular
weight lipopolysaccharide (LPS), ﬁmbriae, proteinases, and low
molecular weight short-chain fatty acids (SCFAs). We previously
showed that SCFAs were responsible for reactivation of KSHV (Yu
et al., 2014). To verify that SCFAs were responsible for induction of
HIV-1 transactivation, we passed the supernatants of Pg and Fn
through YM3 ﬁlters (Millipore), which only allows the low
molecule weight (o3 kDa) SCFAs through. We also heated the
ﬁltered SCFAs containing supernatants of Pg and Fn at 100 1C for
1 h, which effectively removes the volatile SCFAs (Yu et al., 2014).
No difference in the numbers of GFP-positive cells was seen
between 2D10 cells treated with the ﬁltered Fn supernatant and
those treated with unﬁltered Fn supernatants (Fig. 1D). In contrast,
the heated Fn supernatant gave rise to substantially lower num-
bers of GFP-positive cells. Compared to treatment with fresh
medium, the relatively higher number of GFP-positive cells from
treatment with the heated Fn supernatant is likely due to resi-
dual levels of SCFAs in the supernatant after heating (Yu et al.,
2014). Thus, SCFAs in the supernatants of Pg and Fn indeed
were responsible for induction of HIV-1 transactivation in Jurkat
T-cells.
Periodontal pathogens produce multiple SCFAs that induce latent
HIV-1 transactivation
Periodontal pathogens produce at least ﬁve different SCFAs
including butyric acid, isobutyric acid, isovaleric acid, propionic
acid, and acetic acid. The culture supernatants of Pg and Fn contain
millimolar levels of the different SCFAs (Yu et al., 2014). Previous
studies suggested that butyric acid was the sole SCFA that induced
HIV-1 transcription (Imai et al., 2009, 2012c). In contrast to these
reports, we found that the HIV-1 latently infected Jurkat T-cells
(2D10) could respond to each of the SCFAs except acetic acid, in a
dose-dependent manner (Fig. 2A and B). Among the four SCFAs
that induced HIV-1 transactivation, butyric acid had the strongest
effect while isobutyric acid had the weakest effect. When the cells
were treated with different combinations of SCFAs at lower
concentration (0.5 mM), an additive effect of each of these SCFAs
was observed (Fig. 2C).
To examine possible synergy between the different SCFAs, we
conducted systematic synergy assays in 96-well plates by treating
equal numbers of 2D10 cells in each well with two different SCFAs,
each with one of the various concentrations (0, 0.1 mM, 0.25 mM,
0.5 mM, 1.0 mM, 1.5 mM, 2.0 mM, and 2.5 mM). Consistent with
the results shown in Fig. 2C, additive effects were seen between
butyric acid and any of the other SCFAs. A modest synergy
was observed between isovaleric acid and propionic acid at
2.0 mM each (Fig. 3A and B). Together, these results suggest that
all SCFAs but acetic acid contribute to HIV-1 transactivation, dose-
dependently and additively.
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SCFAs induce HIV-1 transcription in primary T-cell models of latency
To examine if SCFAs induce HIV-1 transactivation in primary
CD4þ T-cells, we used a model for HIV latency in primary T-cells
based on a modiﬁed protocol of Bosque and Planelles (Bosque et al.,
2011; Bosque and Planelles, 2009; Kauder et al., 2009). Brieﬂy, naïve
helper T cells were stimulated using α-CD3/α-CD28 mAb and placed
in deﬁned cocktails of cytokines and neutralizing antibodies to
polarize cells into a Th17 phenotype, the principle effector memory
cell found in gut-associated lymphoid tissue. The polarized cells are
then infected using a single round VSV pseudotyped reporter virus,
CD8a-d2EGFP-IRES-Nef (Fig. 4A). This reporter carries the tat, rev, env
and nef genes of HIV-1 clone NL4-3. In addition, the reporter carries a
CD8-d2EGFP fusion protein, which permits cell surface expression of
the N-terminal external domain of CD8 and allows for puriﬁcation of
infected cells with magnetic beads. The polarized cells are then
expanded in the presence of IL-2 and/or IL-23 (for Th17 cells) and the
infected cells are puriﬁed using magnetic activated cell sorting. After
puriﬁcation, the HIV-positive cells are then placed in a step down
cytokine condition, which gradually reduces the cytokine levels and
allows the cells to enter a quiescent cell phenotype. The infected cells
were conﬁrmed to be quiescent by ﬂow cytometry analysis of
expression of Ki67, CD25, CD69 and Cyclin D3 (data not shown),
which are cell cycle arrest markers in these cells (Zack et al., 2013).
The cells were then stained with an AF647-conjugated anti-
body speciﬁc for HIV-1 Nef protein to monitor induction of the
latent HIV provirus (Chang et al., 1998). Once the cells are in
quiescence, the level of HIV Nef protein expression is reduced to
almost undetectable levels (1.38%), which is indicative that the
majority of cells carry latent HIV proviruses (Fig. 4B). GFP levels
also decline compared to freshly infected cells but because of the
high stability of the CD8a-GFP fusion protein a moderate level of
Fig. 2. Different SCFAs induce HIV transactivation dose-dependently and additively. (A) Flow cytometry histograms showing changes in GFP-expression in 2D10 cells upon
treatment with different SCFAs at 5 mM for 24 h. (B) Fraction of GFP-positive cells in 2D10 cells that were treated for 24 h with different concentrations of acetic acid, A;
butyric acid, B; isobutyric acid, IB; isovaleric acid, IV; and propionic acid, P. (C) Fraction of GFP-positive cells in 2D10 cells that were treated with different combinations of
SCFAs at 0.5 mM each for 24 h.
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GFP persists in the quiescent cells. Stimulation of the T-cell
receptor (TCR) by Dynal beads coated with antibodies to CD28
and CD3 activated 95.48% of the cells which appeared in a unique
region of the histogram as Nefþ , GFPhi cells (Fig. 4C). Upon
stimulation with the class 1/2 HDAC inhibitors, SAHA (500 nM,
24 h), there was inefﬁcient activation of the cells resulting in a
minority of cells (18.04%) appearing in the Nefþ , GFPhi region
(Fig. 4D).
The quiescent cells were also treated with Pg supernatant and
fresh medium (control) at different dilutions, as well as a mixture
of ﬁve different SCFAs at 0.1 mM each. Treatment with the mixture
of SCFAs resulted in 81.50% of Nefþ , GFPhi (Fig. 4F). Treatment with
Pg supernatant at 1/100, 1/50, and 1/25 dilutions gave rise to
64.10%, 79.26%, and 91.45% of cells that expressed Nef and d2EGFP
proteins respectively (Fig. 4G, H, and I). These results clearly
demonstrated that SCFAs strongly induce HIV-1 transactivation
in latently infected primary T-cells in a dose-dependent manner.
SCFAs activate P-TEFb to permit proviral reactivation in primary cells
Recent studies show that there is a strict correlation between
the induction of P-TEFb in primary T-cells and the induction of
transcription of latent proviruses (Karn, 2013; Massari et al., 2013;
Mbonye et al., 2013; Novis et al., 2013). In order to monitor P-TEFb
activation (in the same samples evaluated for HIV-Nef induction),
a TRITC-conjugated anti-Cyclin T1 (CycT1) antibody to monitor
synthesis of CycT1 (which leads to assembly of P-TEFb) and an
AF750-conjugated antibody speciﬁc for pSer175, a phosphorylated
form of CDK9 which is associated with transcription and excluded
from the 7SK RNP pool (Mbonye et al., 2013). As expected for
quiescent T-cells, phosphorylation of CDK9 and expression of
CycT1 are highly restricted in the unstimulated cells with only
0.18% of cells expressing phosphorylated CDK9 and CycT1 (Fig. 4B).
Treatment of the cells with Pg supernatant resulted in a dose-
dependent increase in the expression of both markers with 88.17%
of the cells expressing P-TEFb and CycT1 at saturating concentra-
tion (Fig. 4I). Treatment with the mixture of ﬁve SCFAs (0.1 mM
each) also resulted in high P-TEFb activation with 79.70% of the
cells expressing both markers (Fig. 4F).
In contrast, the class-1/2 HDACs inhibitor SAHA only displayed
a modest efﬁciency on P-TEFb activation, rendering 10.72% of the
cells positive for both markers (Fig. 4D). As expected, there is a
strong correlation between the number of CDK9-pS175þ , CycT1þ
cells and the number of Nefþ GFPhi cells, with the vast majority of
cells showing co-expression of all four markers. Thus, SCFAs are
unexpectedly able to potently activate P-TEFb to promote produc-
tive transcription of the latent proviruses in resting memory
T-cells, which constitute the bulk of the HIV reservoir found in
well-suppressed patients.
Because the protein kinase C (PKC) is typically used to upregu-
late P-TEFb activity in cells and PKC agonists promote reactivation of
latent HIV-1 by increasing the level of P-TEFb (Bartholomeeusen
et al., 2013; Bullen et al., 2014; Fujinaga et al., 2012; Mbonye and
Karn, 2014), we reasoned that PKC activation might also play a role
in the SCFA-dependent activation of P-TEFb in primary T-cells. To
test this hypothesis, we treated the quiescent T-cells with fresh
Fig. 3. Isovaleric acid and propionic acid induce HIV-1 transactivation synergistically. (A) Flow cytometry histograms showing changes in GFP expression in 2D10 cells that were
treated with 2 mM isovaleric acid and 2 mM propionic acid, alone or in combination for 24 h. Un-stimulated cells were used as a reference (control). (B) Fraction of GFP-positive
cells in 2D10 cells from synergy assays that were treated with a combination of various concentrations of isovaleric acid and butyric acid (left panel) or propionic acid and isovaleric
acid (right panel). Only additive effects were seen between isovaleric acid and butyric acid while a modest synergy was observed between propionic acid and isovaleric acid at
2 mM each.
B. Das et al. / Virology 474 (2015) 65–81 69
Fig. 4. SCFAs activate P-TEFb and induce HIV-1 transactivation in a primary cell model for HIV-1 latency (Th-17 cells). (A) Schematic diagram of the recombinant HIV-1 virus
used to infect Th-17 cells, which carries a “CD8a-d2EGFP-IRES-Nef” reporter in place of the Nef gene. The internal ribosome entry site (IRES) between d2EGFP and Nef
ensures expression of both GFP and Nef proteins upon transcriptional activation. Infected cells were puriﬁed by antibody selection against CD8a and forced into quiescence
by cytokine withdrawal. (B to I) Flow cytometry histograms showing changes in the numbers of cells expressing HIV-1 Nef protein (AF647 positive) and GFP (upper panels)
or phosphorylated CDK9 (pS175-AF750) and Cyclin T1 (TRITC) (lower panels) upon stimulation. Unstimulated cells (B) were used as a reference. Fresh medium (E) was used
as a bacteria-free control, and TCR activation with dynabeads conjugated to anti-CD3 and anti-CD28 antibodies (C) and treatment with SAHA (500 mM) (D) were used as
positive controls for stimulation of HIV-1 reactivation. A mixture of ﬁve different SCFAs at 0.1 mM each (F) and Pg culture supernatant at 1:100 (G), 1:50 (H), and 1:25
(I) dilution (bacterial supernatant volume vs. total cell culture medium volume) were used to stimulate the cells. Percentages (%) of quiescent cells and activated cells from
each treatment are indicated.
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medium (control), supernatant of Pg, and a mixture of SCFAs at
0.1 mM each in the presence or absence of the PKC inhibitor
Gö6983 (10 mM) for 16 h. P-TEFb and NF-κB activationwas followed
by staining of the cells with anti-pS175 CDK9 and anti-pS529 NF-κB
p65, a phosphoantibody speciﬁc for the nuclear form of NF-κB. In
un-stimulated cells (Fig. 5A) and cells treated with fresh medium
(Fig. 5C), we found no cells that were CDK9 pS175þ , NF-κB pS529þ
in the presence or absence of PKC inhibitor. Cells activated through
TCR activation gave rise to 88.41% CDK9 pS175þ , NF-κB pS529þ
cells. The fraction of activated cells was reduced to 10.85% in the
presence of PKC inhibitor (Fig. 5B). Cells treated with Pg supernatant
at 1:100 and 1:25 dilutions gave rise to 45.55% and 59.88% of CDK9
pS175þ , NF-κB pS529þ cells. The fractions of activated cells were
reduced to 9.15% and 30.67% respectively in the presence of
PKC inhibitor (Fig. 5D and E). It is important to note that although
pS175 activation was almost completely abolished by Gö6983, NF-
κB phosphorylation remained largely unaffected, suggesting that
NF-κB was activated by a PKC-independent pathway induced by
SCFAs. Cells treated with the mixture of SCFAs gave rise to 77.39%
CDK9 pS175þ , NF-κB pS529þ cells, while the proportion of acti-
vated cells was reduced to 19.98% in the presence of the PKC
inhibitor (Fig. 5F). Thus, the bacterial by-products are able to
activate P-TEFb through a PKC-dependent pathway, consistent with
their ability to potently induce latent proviruses.
Saliva from patients with severe periodontal disease contains high
levels of SCFAs and can strongly induce latent HIV-1 proviral
transcription
The gingival crevicular ﬂuids from patients with severe period-
ontal disease contain millimolar levels of SCFAs (Niederman et al.,
1996, 1997). To demonstrate that SCFAs found in oral ﬂuids have
an impact on the host cells to promote HIV-1 transactivation, we
collected saliva from seven patients with severe periodontal
Fig. 5. SCFAs activate P-TEFb via a PKC-dependent pathway. Resting memory T-cells were unstimulated (A) or treated with dynabeads conjugated to anti-CD3 and anti-CD28
antibodies for T-cell receptor activation (B), control media (C), supernatant of Pg at 1:100 and 1:25 dilutions (D and E), and a mixture of SCFAs at 0.1 mM each for 16 h in the
absence (control) or presence of PKC inhibitor Go 6983 (10 mM). The cells were then stained with antibodies to phosphorylated CDK9 (pS175) and NF-κB P65 (pS529), and
analyzed by ﬂow cytometry. Percentages (%) of quiescent and activated cells from each treatment are indicated.
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disease before treatment of the disease and seven individuals
without noticeable periodontal disease as controls. As shown in
Fig. 6A, signiﬁcantly higher levels of butyric acid, isovaleric acid,
propionic acid, and acetic acid were detected in the saliva of
patients with severe periodontal disease.
We treated the HIV-1 latently infected Jurkat cells (2D10) with
saliva from the two groups of participants at 1:5 dilution to assess
their abilities to induce HIV-1 transcription. As shown in Fig. 6B, all
seven saliva samples from patients with severe periodontal dis-
ease highly induced HIV-1 transcription and gave rise to
64.4178.51% of GFP-positive cells. In contrast, the seven saliva
samples from healthy controls only gave rise to 7.1270.62% of
GFP-positive cells. The reason that saliva samples from the control
group also slightly increased the number of GFP-positive cells
when compared to unstimulated cells (1.38% GFP-positive) is likely
due to the fact that these samples also contained low levels of
SCFAs, which may arise from bacterial infections that have not
given rise to clinically signiﬁcant gingivitis. These results suggest
that the signiﬁcantly higher levels of SCFAs in the saliva of patients
with severe periodontal disease indeed promote HIV-1 emergence
from latency.
SCFAs inhibit activity of class-1/2 HDACs
In addition to the restrictions imposed by limiting P-TEFb
levels, latent HIV genomes are silenced through multiple epige-
netic regulatory mechanisms including histone deacetylation and
repressive histone methylation (Hakre et al., 2011; Mbonye and
Karn, 2011; Van Lint et al., 2013). SCFAs are well known inhibitors
of class-1/2 HDACs (Aoyama et al., 2010; Hinnebusch et al., 2002;
Waldecker et al., 2008). Using a class-1/2 HDACs activity assay, we
found that the supernatants of Pg and Fn, but not Ec, substantially
inhibited class-1/2 HDACs activity in Jurkat T-cells (Fig. 7A), which
is in full agreement with previous reports (Imai et al., 2009,
2012c).
SCFAs downregulate the class-3 HDAC SIRT1 and the histone
methyltransferases EZH2 and SUV39H1
To test if SCFAs impact other epigenetic factors to enhance HIV
replication as we demonstrated recently in KSHV infected cells (Yu
et al., 2014), we examined their effects on the class-3 HDACs,
histone methyltransferases and patterns of histone acetylation
and methylation (Fig. 7B). Pg supernatants downregulated expres-
sion of the class-3 HDAC SIRT1 and the histone methyltransferases
EZH2 and SUV39H1, which are responsible for the repressive
histone tri-mehylation marks H3K27me3 and H3K9me3, respec-
tively. As shown in Fig. 7B, the level of SIRT1 in 2D10 cells decreased
as early as 1 h post-treatment with Pg supernatant and progres-
sively decreased after 3 h and 24 h exposure. In parallel, the levels
Fig. 6. Saliva from patients with severe periodontal disease contains signiﬁcantly
higher levels of SCFAs and strongly induces HIV-1 transcription. (A) Levels of
butyric acid, isobutyric acid, isovaleric acid, propionic acid, and acetic acid in saliva
from 7 patients with severe periodontal disease and 7 healthy controls. (B) Fraction
of GFPþ 2D10 cells treated with saliva from 7 patients with severe periodontal
disease and 7 healthy controls at 1:5 dilution (saliva volume vs. total cell culture
medium volume) for 24 h. Un-paired student t test was performed for all
comparisons. Difference with a P valueo0.05 is statistically signiﬁcant.
Fig. 7. SCFAs inhibit class-1/2 HDACs and downregulate expression of class-3 HDAC SIRT1 and the histone lysine methyltransferases EZH2 and SUV39H1. (A) HDAC class 1/2
activity (ﬂuorescence intensity) in Jurkat T-cells that were treated with fresh medium (Med), supernatant of Ec, and ﬁltered supernatants of Pg and Fn at 1:10 dilution for 6 h.
Equal numbers (2.5105) of cells were used for each treatment and subsequent measurement of the relative HDACs activity, using a ﬂuorometric assay kit of Class I&II-
speciﬁc HDACs activity from Sigma-Aldrich. (B and C) Western blot detection of SIRT1, EZH2, SUV39H1, acetylated histone marks H3K9-Ac, H3K27-Ac, H2B-Ac, H4K12-Ac,
repressive histone tri-methylation marks H3K27me3 and H3K9me3, and activating histone tri-methylation mark H3K4me3. 2D10 cells were treated with medium (Med) or
ﬁltered Pg supernatant at 1:10 dilution for 1 h, 3 h, or 24 h. The levels of β-tubulin and total histone-3 (H3) were used as loading controls and references.
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of different histones acetylation marks including H3K9-Ac, H3K27-
Ac, H2B-Ac, and H4K12-Ac increased signiﬁcantly. Similarly, treat-
ment with Pg supernatant also rapidly decreased the levels of EZH2
and SUV39H1. Consequently, the levels of the repressive histone tri-
methylations marks H3K27me3 and H3K9me3 decreased. In con-
trast, treatment with Pg supernatant did not signiﬁcantly increase
the level of the activating histone methylation mark H3K4me3.
To investigate how SCFAs downregulate SIRT1 and EZH2, we
ﬁrst measured their mRNAs levels by real-time RT-PCR in 2D10
cells that were treated with medium (control) or Pg supernatant
for 6 h. As shown in Fig. 8A, the level of SIRT1 mRNAwas 2.6 times
lower in cells that were treated with Pg supernatant, suggesting
that SCFAs suppress SIRT1 transcription. In contrast, the mRNA
level of EZH2 was not signiﬁcantly reduced. Because SCFA-
mediated downregulation of SIRT1 and EZH2 occurred as early
as 1 h post-treatment (Fig. 7B), we suspected that SCFAs might
also cause protein degradation in 2D10 cells. Indeed, consistent
with our previous observations using KSHV-infected human oral
epithelial cells (Yu et al., 2014), treatment of 2D10 cells with
supernatant of Pg resulted in SIRT1 and EZH2 degradation
(Fig. 8B). To conﬁrm that SCFAs cause SIRT1 and EZH2 proteomic
degradation, we treated 2D10 cells with Pg supernatant in the
presence of proteasome inhibitor MG-132 and proteasome inhi-
bitor II (P-inh-II), respectively. As shown in Fig. 8B, both protea-
some inhibitors effectively blocked EZH2 degradation. In contrast,
SIRT1 downregulation could not be completely inhibited by the
two inhibitors, which is consistent with the fact that SCFAs
suppress SIRT1 transcription. Together, these results conﬁrm SCFAs
downregulation of SIRT1 and EZH2 and suggest that these bacter-
ial by-products exert much broader epigenetic impacts than
simply acting as class-1/2 HDACs inhibitors.
We next examined the effects of individual SCFAs on expression
of SIRT1 and EZH2 and histone modiﬁcations. As shown in Fig. 9, all
SCFAs with the exception of acetic acid increased the level of
acetylated H3 (H3K27-Ac). The individual SCFAs also reduced
expression of SIRT1 and EZH2 with a corresponding reduction in
repressive histone mark H3K27me3, in a dose-dependent manner
with butyric acid displaying the highest potency. The different
SCFAs also induced expression of HIV-1 Tat protein in a dose-
dependent manner. Notably, the global changes in histones mod-
iﬁcation marks correlated with Tat expression and the viral trans-
activation patterns shown previously in Fig. 2, further suggesting
that SCFAs induce HIV-1 Tat-dependent transcription by simulta-
neously increasing histone acetylation and decreasing repressive
histone tri-methylation.
Fig. 8. SCFAs inhibit SIRT1 transcription and induce SIRT1 and EZH2 degradation. (A) Relative levels of EZH2 and SIRT1 mRNAs from 2D10 cells that were treated with fresh
medium (Med, control) or ﬁltered Pg supernatant at 1:25 dilution for 6 h. (B) Western blot detection of SIRT1 and EZH2 proteins from 2D10 cells that were treated with
medium (Med) or Pg supernatant at 1:10 dilution in the absence or presence of 2 μM proteasome inhibitor MG-132 and proteasome inhibitor II (P-Inh-II) for 6 h. Beta-tubulin
was used as reference for loading control.
Fig. 9. Western blot detection of SIRT1, EZH2, H3K27-Ac, H3K27me3, HIV-1 Tat
protein, and β-tubulin in 2D10 cells that were treated with different concentrations
(mM) of butyric acid, B; isobutyric acid, IB; propionic acid, P; isovaleric acid, IV and
acetic acid, A for 24 hours.
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SIRT1 and EZH2 are present as a complex at the HIV-1 LTR
We previously demonstrated that EZH2 is involved in epige-
netic silencing of HIV-1 through H3K27 methylation and is present
at the LTR of latent provirus (Friedman et al., 2011). Since both
EZH2 and SIRT1 are simultaneously downregulated by SCFAs, we
examined the possibility that these two proteins could physically
associate with each other. In a co-IP experiment, we precipitated
EZH2 from cell lysates of 2D10 cells that were either treated with
medium (control) or supernatant of Pg for 6 h using a rabbit anti-
EZH2 antibody or control IgG. Data from Western blot analysis of
the co-IP products indicated that the anti-EZH2 antibody pulled
down not only EZH2 and another subunit of the PRC-2, SUZ12, but
also SIRT1 (Fig. 10). In contrast, the control IgG could pull down
neither protein. As expected, both EZH2 and SIRT1 were down-
regulated in cells that were treated with Pg supernatant. These
results suggest that EZH2 and SIRT1 are both components of a
larger Polycomb repressive complex assembled on the proviral
genome, which includes both PRC2 (EZH2) and PRC4 (SIRT1) as
previously suggested (Friedman et al., 2011; Kuzmichev et al.,
2005).
To further test this hypothesis and examine how SCFAs stimu-
lation affects the presence of the EZH2 and SIRT1 complex at the
HIV-1 LTR, we next performed ChIP assays using chromatin
isolated from 2D10 cells treated with medium (control) or Pg
supernatant for 1 h and 6 h respectively. As described previously
the protein distribution on the proviral LTR was measured by using
three pairs of PCR primers speciﬁc for regions within or in the
immediate vicinity of HIV-1 promoter (Friedman et al., 2011;
Jadlowsky et al., 2014; Kim et al., 2011). As controls, one pair of
primers was used to measure DNA outside of the LTR, and another
pair of primers was used to examine the promoter region of the
constitutively expressed housekeeping gene GAPDH.
As shown in Fig. 11, SIRT1 and EZH2 are present at the HIV-1
promoter and its vicinity in latently infected cells. Upon treatment
with Pg supernatant, they are removed from the LTR within 1 h.
Consistent with these results, the levels of acetylated histone
marks H4K12-Ac and H2B-Ac were increased in LTR upon stimula-
tion with Pg supernatant while the level of suppressive histone
marks H3K27me3 and H3K9me3 were reduced. These changes in
histone marks were coupled with increased recruitment of RNA
polymerase II (RNAP II). In contrast to antibodies speciﬁc for the
different histone marks, ChIP assays performed with the control
IgG pulled down 10-fold lower amounts of DNA and there were no
obvious differences between cells with and without stimulation.
Collectively, these results conﬁrm that SCFAs modulate multiple
epigenetic regulators to induce different histone modiﬁcations
including increased levels of histone acetylation marks and
decreased levels of repressive histone tri-methylation marks in the
LTR to promote HIV-1 transactivation.
Knock-down or inhibition of SIRT1 induces HIV-1 transactivation
The role of SIRT1 in controlling HIV-1 silencing and transacti-
vation has been controversial (Pagans et al., 2005; Pinzone et al.,
2013; Zhang and Wu, 2009). To verify that SCFAs downregulation
of SIRT1 contributes to HIV-1 induction, we infected 2D10 cells
with lentiviruses expressing ﬁve different SIRT1-peciﬁc shRNAs
and a control shRNA. The fraction of GFP-positive cells increased
signiﬁcantly in all the cells transduced with the individual SIRT1-
speciﬁc shRNAs compared to cells transduced with the control
shRNA (Fig. 12A and B), suggesting that knock-down of SIRT1
expression is sufﬁcient to induce HIV-1 transactivation. As
expected all ﬁve SIRT1-speciﬁc shRNAs effectively knocked down
expression in 2D10 cells (Fig. 12C).
To further conﬁrm the involvement of SIRT1 in HIV-1 latency,
we next treated 2D10 cells with SIRT1 inhibitor Sirtinol (10 μM) in
the presence or absence of the class-1/2 HDACs inhibitor SAHA
(0.5 μM). Both Sirtinol and SAHA increased the numbers of GFP-
positive cells (Fig. 13A and B), and the combination of SAHA and
Sirtinol further increased the numbers of GFP-positive cells in an
additive manner. Thus, SIRT1 appears to contribute directly to HIV
latency and suppression of SIRT1 induces HIV-1 transactivation.
Discussion
Induction of HIV transcription by bacterial SCFAs
Although HARRT can effectively inhibit HIV replication and
limit the viral load to nearly undetectable levels in HIV patients,
sporadic reactivation of the latent virus can still occur and many
patients show “blips” of viremia during the course of their
treatment. This is particularly true in HIV patients who have
severe periodontal disease, in which the milieu of pathogenic
bacterial infection and chronic inﬂammation appears to enhance
HIV replication. Not only are more periodontal pathogens such as
Pg found in HIV-positive individuals than in healthy controls
(Chattin et al., 1999; Scully et al., 1999), but there was a signiﬁcant
correlation between the clinical stage of periodontitis and HIV-1
proviral DNA load in the gingival crevicular ﬂuid and HIV-1 viral
RNA load in the plasma and saliva (Maticic et al., 2000; Shugars
et al., 2000). The interactions between periodontal pathogens and
HIV are therefore likely to create a vicious cycle of enhanced viral
induction and bacterial replication in the oral cavity of HIV
patients.
Understanding the molecular mechanisms of this microbial
interaction may hold the key to developing effective treatment for
both periodontal disease and limiting viral infection in the oral
cavity of HIV patients. In this study, we demonstrated that SCFAs
from anaerobic gram-negative bacteria such as Pg and Fn very
Fig. 10. SIRT1 and EZH2 are present as a complex in HIV-1 latently infected Jurkat T-cells. Total proteins extracts from equal numbers (2106) of HIV-1 latently infected
Jurkat T-cells (2D10) that were treated with fresh medium (control) or ﬁltered Pg supernatant at 1:25 dilution for 6 h were immuno-precipitated (IP) with a rabbit anti-EZH2
polyclonal antibody or control rabbit IgG. The input protein samples and the resulting IP products were then subjected to SDS-PAGE and Western blot detection with
antibodies to SIRT1, EZH2 or another PRC2 subunit, SUZ12.
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strongly induced HIV-1 transactivation in latently infected T-cells.
Importantly, similar activities were found in both Jurkat T-cell
models of latency and in primary T-cells. One of the SCFAs, butyric
acid, has been previously reported to promote HIV transactivation
by inhibiting class-1/2 histone deacetylases (HDACs) (Imai et al.,
2012a, 2009, 2012c; Kantor et al., 2009), leading to histone
hyperacetylation and induction of viral gene expression and
replication. However, in contrast to the previous reports, we found
that all SCFAs, with the exception of acetic acid, induced HIV-1
transactivation in a dose-dependent manner.
Most of the different SCFAs exhibited additive effects while
isovaleric acid and propionic acid displayed a modest synergy. In a
highly inﬂammatory microenvironment such as periodontal dis-
ease, excessive amounts of inﬁltrating inﬂammatory cells and
lymphocytes, including HIV-latently infected CD4þ T-cells
(Fenouillet et al., 1989; Le Naour et al., 1992; Mabondzo et al.,
1991; Neuveut et al., 1991; von Briesen et al., 1990), could be
present in the oral arena of HIV patients. Because millimolar levels
of the different SCFAs are simultaneously present in the gingival
crevicular ﬂuid and saliva of patients with severe periodontal
disease, these bacterial by-products may act together to constantly
stimulate the HIV-latently infected CD4þ T-cells to induce HIV
transactivation and promote productive viral replication. Our
ﬁnding that saliva from patients with severe periodontal disease
very strongly induced HIV transactivation in HIV-1 latently
infected Jurkat T-cells in vitro further supports this notion. The
oral cavity of HIV patients could therefore be an important viral
source for recurrent HIV induction. It is, therefore, necessary to
take the interaction between periodontal pathogens and HIV into
consideration when it comes to ﬁnding strategies for improving
anti-viral therapy and eradication of the latent HIV reservoir.
SCFAs activate P-TEFb: A novel mechanism for HIV-1 transactivation
in primary T-cells
In primary resting T-cells, RNA polymerase II transcription
elongation and Tat activity is highly restricted due to very low levels
of P-TEFb expression in the quiescent cells (Chiang et al., 2012;
Herrmann et al., 1998; Ramakrishnan et al., 2009; Ramakrishnan
and Rice, 2011). P-TEFb is a heterodimer of the CDK9 serine/
threonine kinase and a C-type regulatory cyclin, Cyclin T1 (CycT1).
Human Cyclin T1 (hCycT1) binds directly to Tat and enhances the
co-operative binding of P-TEFb/Tat to TAR RNA by binding to its
apical loop (Bieniasz et al., 1998; Fujinaga et al., 1999; Wei et al.,
1998). P-TEFb is then able to stimulate HIV transcription elongation
by phosphorylating a variety of positive and negative factors. For
positive regulation, hyperphosphorylation of serine residues of the
heptad repeats at the CTD of RNAP II by Tat-stimulated P-TEFb
enhances its processivity (Isel and Karn, 1999; Kim et al., 2002;
Marciniak and Sharp, 1991; Parada and Roeder, 1996). Similarly,
phosphorylation of the C-terminal region of the SPT5 subunit of DSIF
by P-TEFb transforms it into a positive elongation factor (Bourgeois
et al., 2002; Yamada et al., 2006). Removal of transcriptional blocks
is due to the phosphorylation of the E-subunit of the negative
Fig. 11. SCFAs simultaneously increase histone acetylation and decrease repressive histone tri-methylation in the HIV-1 promoter. Chromatin was isolated from equal
numbers (6107) of HIV-1 latently infected Jurkat T-cells (2D10) treated with fresh medium (control) or ﬁltered Pg supernatant at 1:25 dilution for 1 h or 6 h. After
sonication, DNA fragments were immuno-precipitated with antibodies to SIRT1, EZH2, H3, H4K12-Ac, H2B-Ac, H3K27me3 H3K9me3, RNA polymerase II (RNAP II) or control
IgG. DNA was ampliﬁed by real-time PCR using primers speciﬁc for the Nuc-0 (390 to 383), HIV-1 promoter (116 to þ4) and Nuc-1 (þ30 to þ134) regions. Primers
speciﬁc for region outside of the HIV-1 LTR (þ611 to þ770) and primers for the host house-keeping gene GAPDH were used as controls. Data was expressed as a fraction of
the sample input DNA. Error bars represent the standard deviations of three repeats of real-time PCR measurement.
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elongation factor NELF by P-TEFb which forces its dissociation from
paused RNAP II complexes and allows resumption of productive
elongation (Fujinaga et al., 2004; Jadlowsky et al., 2014; Natarajan
et al., 2013). It has also been recently discovered that Tat mediates the
recruitment of a large “super elongation complex” containing numerous
additional elongation factors (He et al., 2011, 2010; Liu et al., 2012;
Sobhian et al., 2010).
Using a primary CD4þ T-cell model of HIV-1 latency, we found
unexpectedly that SCFAs are capable of inducing phosphorylation
of CDK9 at Ser175, a modiﬁcation that we have previously shown
is associated with the transcriptionally active form of P-TEFb
(Mbonye et al., 2013b). In addition, SCFAs also strongly induce
CycT1 expression, further suggesting that these bacterial by-
products activate P-TEFb to promote transcription elongation of
the integrated provirus. Importantly, we found that the PKC
inhibitor Gö6983 strongly inhibits SFCA-dependent activation of
P-TEFb, without blocking NF-κB activation, indicating that PKC
mediates SCFAs activation of P-TEFb. While the roles of PKC in
activation of P-TEFb and HIV-1 transactivation is extremely well
documented (Bartholomeeusen et al., 2013; Fujinaga et al., 2012;
Mbonye and Karn, 2014), how SCFAs impact the PKC signaling
pathway remains to be determined. One possibility is that SCFAs
bind to their cellular receptors GPR41 and/or GPR43, which are G-
protein coupled receptors (Eberle et al., 2014; Kimura et al., 2014)
that are known to activate PKC upon stimulation with GPCR
agonists (Naor et al., 2000; Rozengurt, 2007). This type of
mechanism may explain why SCFAs activate P-TEFb much more
efﬁciently than SAHA (Fig. 4), a HDACs inhibitor that is just as
potent as SCFAs in inducing histone modiﬁcations. In summary,
our results highlight an additional unexpected mechanism of
SCFAs for the induction of HIV-1 transactivation involving the
induction of P-TEFb in resting primary T-cells.
Fig. 12. Knockdown of SIRT1 induces HIV-1 transcription. (A) Flow cytometry showing changes in GFP-expression in 2D10 cells that were infected with lentiviruses
expressing ﬁve SIRT1-speciﬁc shRNAs or control shRNA. (B) Mean percentages (%) of GFP-positive cells from 2D10 cells that were transduced with lentiviruses expressing ﬁve
different SIRT1-speciﬁc shRNAs or control shRNA. (C) Western blot detection of SIRT1 and beta-tubulin from 2D10 cells that were transduced with lentiviruses expressing
ﬁve different SIRT1-speciﬁc shRNAs or control shRNA.
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Regulation of SIRT1, EZH2 and SUV39H1 by SCFAs
SCFAs are well-known for their ability to inhibit class-1/2
HDACs, which results in histone hyperacetylation and promote
gene expression (Chen et al., 2003; Kuzmichev et al., 2005; Santini
et al., 2007). Previous studies have associated the ability of SCFAs
to inhibit class-1/2 with the induction of HIV-1 transcription (Imai
et al., 2009, 2012c; Kantor et al., 2009). However, complete
silencing of HIV genome involves multiple epigenetic silencing
mechanisms including DNA methylation and speciﬁc patterns of
histone methylation (Hakre et al., 2011; Mbonye and Karn, 2011;
Van Lint et al., 2013). In order to assess the broader epigenetic
effects of SCFAs, we investigated whether these molecules also
impact the class-3 HDAC SIRT1 and the histone methyltransferases
EZH2 and SUV39H1. We found surprisingly that SCFAs not only
inhibit the activity of class-1/2 HDACs but also downregulate
expression of SIRT1, EZH2, and SUV39H1, leading to concomitant
increases in the levels of histone acetylation and decreases in the
levels of the repressive histone marks H3K27me3 and H3K9me3.
SCFAs both directly inhibit SIRT1 transcription and cause proteo-
mic degradation of the SIRT1 and EZH2 proteins.
Importantly, data from co-IP and ChIP experiments indicate
that SIRT1 and EZH2 interact with each other and are present as
part of a large complex recruited to the LTR of HIV-1 proviral
genomes during latent infections. Treatment of cells with SCFAs
reduces expression of both proteins and rapidly lowers their
presence in the viral LTR. In consequence, the levels of acetylated
histones such as H4K12-Ac and H2B-Ac increase while the level of
repressive histone mark H3K27me3 decrease in the viral promoter
region following SCFA exposure. Thus, SCFAs not only suppress
HDACs to increase histone acetylation but also downregulate EZH2
to decrease repressive histone methylation at speciﬁc viral chro-
matins to induce HIV-1 transactivation.
These data conﬁrm and extends our previous ﬁnding that transcrip-
tion silencing complex PRC2 plays an important role in silencing HIV-1
genome (Friedman et al., 2011). The association of EZH2 and SIRT1 in a
complex at the HIV-1 promoter region is unexpected but may reﬂect
interactions between PRC2 and the SIRT1-containing PRC4 complex
suggested previously (Kuzmichev et al., 2005). Based on these new
ﬁndings, we conclude that the mechanism of SCFAs induction of viral
replication is far more complicated than simply acting as HDACs
inhibitors as previously claimed. Instead, these bacterial by-products
modulate multiple components of the host epigenetic regulatory
machinery to orchestrate viral transactivation by inducing multiple
histone modiﬁcations including increased histone acetylation and
decreased repressive histone methylation.
The role of SIRT1 in HIV transcription is only poorly under-
stood. Multiple studies have demonstrated that HIV-1 Tat protein
is a substrate of SIRT1 for deacetylation and functional inhibition
or knockdown of SIRT1 is known to enhance Tat’s ability to
transactivate HIV-1 (Pinzone et al., 2013; Zhang et al., 2010;
Zhang and Wu, 2009). By contrast, in SIRT1-null mouse cells,
where there is no SIRT1 expression, Tat transactivation is defective
but can be rescued by expression of SIRT1 (Pagans et al., 2005).
SIRT1 is also known to deacetylate lysine 310 in the p65 subunit of
nuclear factor-κB (NF-κB), and inhibition of SIRT1 results in
acetylation of p65 and activation of the NF-κB pathway and
enhancement of HIV transcription (Kwon et al., 2008).
Our results are consistent with a dual role for SIRT1. Functional
inhibition by SCFAs or Sirtinol, or knockdown of SIRT1 expression
by shRNA, results in the induction of latent HIV proviral transcrip-
tion, suggesting that SIRT1 contributes to HIV-1 latency. For
example, reduced levels of SIRT1 may enhance Tat activity through
the accumulation of acetylated Tat protein. However, we hypothe-
size that residual SIRT1 is required in these experiments in order
to support HIV transcription. Consistent with this idea, the ChIP
assays showed an increased level of SIRT1 at the HIV-1 LTR at 6 h
post-treatment with Pg supernatant compared to 1 h post-
treatment. It seems likely that this increase is due to the recycling
of a SIRT1-Tat complex used during HIV-1 transactivation.
Conclusion
We have demonstrated that multiple SCFAs from periodontal
bacteria can act as potent activators of latent HIV-1 transactivation in
both cell models and latently infected primary cells. Our study
reveals novel mechanisms that allow these bacterial metabolic
by-products to create a permissive environment of HIV transcription
by upregulating P-TEFb and downregulating the epigenetic silencing
machinery. These new ﬁndings provide further insights into the
epidemiological links between chronic periodontitis and increased
HIV replication in the oral cavity and highlight the importance of
treating periodontal disease in HIV-infected patients.
Fig. 13. Inhibition of SIRT1 activity induces HIV-1 transactivation. (A) Flow cyto-
metry histograms showing changes in GFP-expression in 2D10 cells that were
treated with SIRT1 inhibitor Sirtinol (10 μM) and the class-1/2 HDACs inhibitor
SAHA (0.5 μM), alone or in combination for 24 h, in comparison to cells treated
with placebo (DMSO, control). (B) Fraction of GFP-positive cells in 2D10 cells that
were treated with Sirtinol and SAHA, alone or in combination.
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Materials and methods
Reagents
Molecular grade SCFAs butyric acid, isobutyric acid, isovaleric
acid, propionic acid, and acetic acid, proteomic inhibitor MG132,
SIRT1 inhibitors Sirtinol, class-1/2 HDACs inhibitor suberoyanilide
hydroxamic acid (SAHA), and EZH2 inhibitor UNC were purchased
from Sigma-Aldrich. Antibodies against EZH2, SIRT1, SUV39H1,
RNA polymerase II, histone-3 (H3), acetylated histones including
H3K27-Ac, H3K9-Ac, H4K12-Ac, and H2B-Ac, repressive histone
marks H3K27me3 and H3K9me3, and activating histone methyla-
tion mark H3K4me3 were purchased from Millipore.
Cell culture
2D10 cells are a clone of Jurkat T-cells that is latently infected
with a defective recombinant HIV-1 carrying a d2EGFP reporter
protein to monitor viral transactivation (Pearson et al., 2008).
2D10 cells were cultured in RPMI 1640 medium supplemented
with 10% fetal bovine serum (FBS), penicillin (100 IU/ml), strepto-
mycin (100 μg/ml) and 25 mM HEPES in 5% CO2 at 37 1C.
To test the efﬁciency of SCFAs on HIV-1 latency in primary
T-cells, a polarized model of HIV-1 latency modiﬁed from a
previously described method was generated based on the methods
of Bosque and Planelles (Bosque et al., 2011; Bosque and Planelles,
2008; Kauder et al., 2009). Brieﬂy, naïve primary CD4þ T-cells
from healthy donors were isolated from leukapheresis packs,
activated by anti-CD3/CD28 stimulation of the TCR and polarized
into a Th-17 cell phenotype. During the exponential growth phase,
the cells were infected by a recombinant HIV-1 carrying a CD8-
EGFP fusion protein using spinoculation. The infected cells were
puriﬁed on magnetic beads and then allowed to enter quiescence
by placing the cells in a restrictive cytokine environment. Cells
were demonstrated to be quiescent prior to exposure to SCFAs by
monitoring CD25, CD69 and CyclinD3 levels using ﬂow cytometry.
Bacterial strains and culture conditions
Periodontopathgens Pg (ATCC 33277) and Fn (ATCC 25586)
were maintained in blood agar plates (Fisher) and grown in
Enriched Trypticase Doy Broth (ETDB) as described previously
(Syed, 1980) in an anaerobic system (5% CO2, 10% H2, and 85% N2 at
37 1C) to a late log phase. The supernatants were collected by
centrifugation at 10,000 x g for 10 min at 4 1C to remove bacteria,
followed by sterilization through a 0.22 μm pore size membrane
ﬁlter. Escherichia coli (Ec) were cultured in LB medium under
aerobic condition (37 1C with shaking). Under such condition, no
SCFA was detected in the culture supernatant of Ec.
Assessment of periodontal disease and collection of saliva
We used a protocol that is very similar to what has been reported
(Vernon et al., 2009) to deﬁne and assess the severity of periodontal
disease of all recruited participants, which includes: (1) probing depth
(PD) and clinical attachment level (CAL) at six sites per tooth; (2)
gingival recession; and (3) percentage of sites with bleeding on probing
(BOP). The study was performed by fully following an IRB protocol (IRB-
2012-253, Epigenetic regulation of viral replication by periodontal
bacteria) approved by the Ethics Committee of Case Western Reserve
University and with the written consent of all participants. Participants
having CALZ6mm with at least 5mm PD in 30% of the sites were
considered as patients with severe periodontal disease. Participants
having CALr2mm with PDr3mm on all teeth were selected as
healthy controls. About 5ml saliva was collected from each participant.
After centrifugation to remove cells and debris, the supernatant of the
collected saliva was sterilized by passing through a 0.22 μm ﬁlter, which
was either used immediately for experiment or stored at 80 1C.
Quantiﬁcation of SCFAs
Gas phase chromatography was used to determine the con-
centrations of butyric acid, isobutyric acid, isovaleric acid, propio-
nic acid, and acetic acid in the collected saliva, as described
previously (Niederman et al., 1996, 1997). A series of dilutions of
each of the pure SCFAs were ﬁrst run to establish a standard curve
reﬂecting the correlation between signal pick area and the con-
centration of the analyte, and the concentration of the analyte in
the sample was determined by comparing its pick area with the
standard curve. The concentration of the SCFA in question for a
given sample was calculated as the average value from triplicate
measurement.
Co-immunoprecipitation (co-IP) and Western blot analysis
HIV-1 latently infected Jurkat T-cells (2106 cell/ml) were
treated with Pg supernatants or fresh medium (control) at 1
(supernatant volume) to 25 (total cell culture medium volume)
dilution for 6 h. The cells were harvested and re-suspended in ice
cold lysis buffer containing 400 mM NaCl, 1 mM EDTA, 1 mM DTT,
100 mM Tris–HCl (pH 7.4), 0.5% Triton-X, 0.2% NP-40, and protei-
nase inhibitors cocktail, and incubated on ice for 30 min. After
centrifugation (10,000 g, 10 min), the supernatants were collected
and incubated with a rabbit polyclonal anti-EZH2 antibody or
control rabbit IgG at 4 1C for overnight with shaking, followed by
adding Protein-A/Protein-G agarose beads and incubation at room
temperature for 2 h. After two rounds of washing with the lysis
buffer and two rounds of washing with phosphate saline, the
protein-antibody complexes were eluted in lysis buffer plus 2%
SDS and subjected to SDS-PAGE analysis and Western blot analysis.
Measurement of HIV-1 transactivation by ﬂow cytometry
To determine the efﬁciency of SCFAs in inducing HIV-1 trans-
activation, HIV-1 latently infected Jurkat T-cell line 2D10 was
stimulated with various doses of SCFAs or bacterial supernatants
at different dilutions. The cells were then washed in Auto-MACs
running buffer and the numbers of cells with d2EGFP expression
were determined by ﬂow cytomerty (BD LSRFortessa cell analyzer)
analysis.
To measure HIV-1 transactivation in primary T-cells that were
latently infected with HIV-1, following stimulation with bacterial
supernatants or SCFAs, the cells were stained for HIV-1 Nef protein
expression by using an AF647 conjugated antibody to Nef protein
(AIDS Reagents, Item#709), an AF750 conjugated antibody to
phosphorylated pTEF-b (pS175) (Mbonye et al., 2013), and a
TRITC-conjugated antibody to Cyclin T1 (Santa Cruz Biotechnology,
Inc), followed by ﬂow cytometry quantiﬁcation of Nef-positive,
pS175-positive, and Cyclin T1-positive cells.
HDAC activity assay
Measurement of the relative activity of class-1/2 HDACs was
conducted by using a ﬂuorometric histone deacetylase assay kit
from Sigma-Aldrich following the manufacturer's instruction.
Equal numbers (2.5105) of Jurkat T-cells were treated with fresh
medium, supernatant of non-oral bacteria Ec, and supernatants of
Pg and Fn at 1 (bacterial supernatant volume) to 25 (total cell
culture medium volume) dilution for 6 h. The cells were harvested
and re-suspended in the assay buffer, then loaded in 96-well plate.
Upon incubation with the substrate, the plate was read under a
ﬂuorimeter at excitation wavelength of 380 nm and emission
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wavelength of 480 nm. The relative HDACs activity of the sample is
represented as the mean value of ﬂuorescence intensity from three
repeats.
Isolation of total RNAs and quantiﬁcation of mRNA by qRT-PCR
Total RNAs from HIV-1 latently infected Jurkat T-cells (2D10) were
isolated using a RNA puriﬁcation kit from QIAGEN, which includes a
step to remove residual genomic DNA prior to RNA puriﬁcation. Reverse
transcription (RT) of total RNA was performed by using Superscript
Transcriptase II (Invitrogen, Carlsbad, CA). Quantitative RT-PCR was
performed to measure the relative levels of SIRT1 and EZH2 mRNAs
using the following pairs of primers:
50CCTGACTTCAGATCAAGAGACGGTA30 (SIRT1 forward) and
50CTGATTAAAAATGTCTCCACGAACAG03 (SIRT1 reverse); and 2)
50GTGGAGAGATTATTTCTCAAGATG30 (EZH2 forward) and 50CCG-
ACATACTTCAGGGCATCAGCC30 (EZH2 reverse). The mRNA level of
the house-keeping gene β-actin was used as reference for normal-
ization and determined by using the primers 50ATTGCCGA-
CAGGATGCAGA30 (actin forward) and 50GAGTACTTGCGCTCAG-
GAGGA30 (actin reverse). All qRT-PCR reactions consist of three
repeats.
Chromatin immuno-precipitation (ChIP) assay
Equal numbers of HIV-1 latently infected Jurkat T-cells 2D10
(6107) were treated with ﬁltered culture supernatant of Pg or
fresh medium (control) at 1 (supernatant volume) to 25 (total cell
culture medium volume) dilution for 1 h and 6 h respectively,
followed by ﬁxation with 0.5% formaldehyde for 15 min. Prepara-
tion of chromatin suspensions from these cells and ChIP were
conducted by using a ChIP assay kit from Invitrogen and following
instruction from the manufacture. Antibodies against EZH2, SIRT1,
RNA polymerase II (RNAP II), total histone-3 (H3), acetylated
histones (H4K12-Ac and H2B-Ac), and methylated histone-3
(H3K27me3 and H3K9me3), all from Millipore, were used for the
procedure. DNA from input and the end ChIP products were
isolated by using DNA puriﬁcation kit from QIAGEN. The puriﬁed
DNA were re-suspended in 100 μl sterile water and used for real-
time PCR quantiﬁcation of DNA fragments within or in the vicinity
of the HIV promoter region in LRT. Primers and their genomic
locations were as described previously (Friedman et al., 2011).
Lentiviruses expressing SIRT1 speciﬁc shRNA
For efﬁcient knock-down of SIRT1 protein expression in latently
infected 2D10 cells, Puromycin selection marker containing pLKO.1
vector harboring speciﬁc shRNA sequence against SIRT1 (MISSION
shRNA constructs from SIGMA-Aldrich) were used. Vesicular
stomatitis viruses G-pseudotyped were produced with shRNAs
sequences that speciﬁcally target SIRT1 mRNA to knockdown their
expression, in HEK 293T cell line using Lipofectamine as described
previously (Kim et al., 2006). The sequences of the ﬁve SIRT1
speciﬁc shRNAs were the followings:
(1) 50GTACCGGCATGAAGTGCCTCAGATATTACTCGAGTAATATCTGA-
GGCACTTCA TGTTTTTTG30 (shRNA34);
(2) 50CCGGGCAAAGCCTTTCTGAATCTATCTCGAGATAGATTCAGAAA-
GGCTTTGC TTTTT30 (shRNA79);
(3) 50CCGGCCTCGAACAATTCTTAAAGATCTCGAGATCTTTAAGAATT-
GTTCGAG GTTTTT30 (shRNA80);
(4) 50CCGGGCGGGAATCCAAAGGATAATTCTCGAGAATTATCCTTTG-
GATTCCCGC TTTTT30 (shRNA81); and
(5) 50CCGGGCGGCTTGATGGTAATCAGTACTCGAGTACTGATTACCAT-
CAAG CCGCTTTTT30 (shRNA83). A control shRNA lentivirus was
made with the following sequence: 50ACCGGGCGCGATAGC
GCTAATAATTTCTCGAGAAATTATTAGCGCTATCGCGCTTTTT30.
The virus titers were determined by infecting 1106 Jurkat
T-cell with a serial dilution of concentrated and puriﬁed virus
stocks from harvested culture supernatant by ultra-centrifugation.
The virus MOI was determined by using Lentivirus qPCR Titer kit
from Applied Biological Materials Inc., following the manufac-
turer’s instruction. To knock-down the expression of SIRT1 protein,
latently infected 2D10 cells were infected with 3.6106 IU MOI of
shRNA containing virus for 16 h. The transduced cells were then
washed in fresh RPMI 1640 complete medium and re-suspended
in 2 mg/ml Puromycin containing medium for selection and main-
tenance of shRNA transduced cells. Expression of SIRT1 after
shRNA knock-down was veriﬁed by Western blot analysis with a
SIRT1-speciﬁc antibody.
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